<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080651</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCPT09_Vori2C19_B</org_study_id>
    <nct_id>NCT01080651</nct_id>
  </id_info>
  <brief_title>Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole</brief_title>
  <official_title>Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the drug-drug interaction between rifampicin and voriconazole according to&#xD;
      CYP2C19 genotype quantitatively following a single oral administration of 200 mg voriconazole&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of voriconazole</measure>
    <time_frame>pre-dose, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h post-dose</time_frame>
    <description>Sample for concentration measurement conducted before and after rifampicin treatment as same manner</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>CYP2C19 extensive metabolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2C19 poor metabolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration</description>
    <arm_group_label>CYP2C19 extensive metabolizer</arm_group_label>
    <arm_group_label>CYP2C19 poor metabolizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Healthy male subjects aged 20 - 50 years.&#xD;
&#xD;
          -  2.A body mass index (BMI) in the range 17-28 kg/m2.&#xD;
&#xD;
          -  3.Sufficient ability to understand the nature of the study and any hazards of&#xD;
             participating in it. Provide written informed consent after being fully informed about&#xD;
             the study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Presence or history of severe adverse reaction to any drug or a history of severe&#xD;
             allergic disease.&#xD;
&#xD;
          -  2.Clinically relevant abnormal medical history that could interfere with the&#xD;
             objectives of the study.&#xD;
&#xD;
          -  3.Presence or history of eye disease or eye field defect.&#xD;
&#xD;
          -  4.A subject with history of gastrointestinal disease or surgery (except simple&#xD;
             appendectomy or repair of hernia), which can influence the absorption of the study&#xD;
             drug.&#xD;
&#xD;
          -  5.A subject whose liver function test (AST, ALT, GGT, ALP, LDH) result is over 1.25&#xD;
             times of upper limit of normal range.&#xD;
&#xD;
          -  6.A subject whose SBP is over 140 mmHg or below 90 mmHg and DBP is over 100 mmHg or&#xD;
             below 50 mmHg.&#xD;
&#xD;
          -  7.Presence or history of drug abuse.&#xD;
&#xD;
          -  8.Participation in other clinical trial within 2 months.&#xD;
&#xD;
          -  9.Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter&#xD;
             medication within 1 week before first dose.&#xD;
&#xD;
          -  10.Blood donation during 2 months or apheresis during 1 month before the study.&#xD;
&#xD;
          -  11.Presence or history of alcohol abuse.&#xD;
&#xD;
          -  12.Smoking of more than 10 cigarettes/day.&#xD;
&#xD;
          -  13.Use of grapefruit juice, xanthine containing beverage, alcohol or smoking during&#xD;
             restriction period.&#xD;
&#xD;
          -  14.Subject judged not eligible for study participation by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>In-Jin Jang</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

